Us Bancorp \De\ Krystal Biotech, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 945 shares of KRYS stock, worth $168,304. This represents 0.0% of its overall portfolio holdings.

Number of Shares

945

Previous 1,763 46.4%

Holding current value

$168,304

Previous $323,000 47.06%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$174.7 - $213.66 $142,904 - $174,773	-818 Reduced 46.4%	945 $171,000
Q2 2024 Aug 06, 2024	SELL	$153.12 - $183.64 $5,206 - $6,243	-34 Reduced 1.89%	1,763 $323,000
Q1 2024 May 07, 2024	BUY	$108.01 - $179.35 $18,685 - $31,027	173 Added 10.65%	1,797 $319,000
Q4 2023 Feb 09, 2024	BUY	$96.0 - $128.29 $137,760 - $184,096	1,435 Added 759.26%	1,624 $201,000
Q2 2023 Aug 09, 2023	BUY	$78.48 - $130.32 $784 - $1,303	10 Added 5.59%	189 $22,000
Q1 2023 May 09, 2023	SELL	$72.39 - $84.27 $941 - $1,095	-13 Reduced 6.77%	179 $14,000
Q4 2022 Feb 13, 2023	SELL	$63.14 - $79.9 $3,030 - $3,835	-48 Reduced 20.0%	192 $15,000
Q3 2022 Oct 27, 2022	SELL	$64.85 - $82.4 $10,765 - $13,678	-166 Reduced 40.89%	240 $17,000
Q2 2022 Aug 01, 2022	SELL	$48.93 - $73.47 $12,966 - $19,469	-265 Reduced 39.49%	406 $27,000
Q1 2022 May 11, 2022	SELL	$51.99 - $72.11 $8,526 - $11,826	-164 Reduced 19.64%	671 $45,000
Q4 2021 Feb 11, 2022	BUY	$39.81 - $88.24 $28,862 - $63,973	725 Added 659.09%	835 $58,000
Q3 2021 Nov 10, 2021	BUY	$52.01 - $71.77 $832 - $1,148	16 Added 17.02%	110 $6,000
Q2 2021 Aug 05, 2021	SELL	$62.14 - $81.82 $6,897 - $9,082	-111 Reduced 54.15%	94 $6,000
Q2 2020 Aug 07, 2020	BUY	$37.03 - $60.0 $7,591 - $12,300	205 New	205 $8,000

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account